Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.
Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC. Jacobson JM, et al. Among authors: rotshteyn y. Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42. doi: 10.1128/AAC.00086-10. Epub 2010 Jul 26. Antimicrob Agents Chemother. 2010. PMID: 20660677 Free PMC article. Clinical Trial.
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC. Jacobson JM, et al. Among authors: rotshteyn y. J Infect Dis. 2008 Nov 1;198(9):1345-52. doi: 10.1086/592169. J Infect Dis. 2008. PMID: 18771406 Clinical Trial.
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Petrylak DP, Kantoff P, Vogelzang NJ, Mega A, Fleming MT, Stephenson JJ Jr, Frank R, Shore ND, Dreicer R, McClay EF, Berry WR, Agarwal M, DiPippo VA, Rotshteyn Y, Stambler N, Olson WC, Morris SA, Israel RJ. Petrylak DP, et al. Among authors: rotshteyn y. Prostate. 2019 May;79(6):604-613. doi: 10.1002/pros.23765. Epub 2019 Jan 20. Prostate. 2019. PMID: 30663074 Clinical Trial.
Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers.
Gale DD, Landells LJ, Spina D, Miller AJ, Smith K, Nichols T, Rotshteyn Y, Tonelli A, Lacouture P, Burch RM, Page CP, O'Connor BJ. Gale DD, et al. Among authors: rotshteyn y. Br J Clin Pharmacol. 2002 Nov;54(5):478-84. doi: 10.1046/j.1365-2125.2002.01682.x. Br J Clin Pharmacol. 2002. PMID: 12445026 Free PMC article. Clinical Trial.
Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans.
Chandrasekaran A, Tong Z, Li H, Erve JC, DeMaio W, Goljer I, McConnell O, Rotshteyn Y, Hultin T, Talaat R, Scatina J. Chandrasekaran A, et al. Among authors: rotshteyn y. Drug Metab Dispos. 2010 Apr;38(4):606-16. doi: 10.1124/dmd.109.031179. Epub 2010 Jan 6. Drug Metab Dispos. 2010. PMID: 20053817 Clinical Trial.
Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.
Gale DD, Hofer P, Spina D, Seeds EA, Banner KH, Harrison S, Douglas G, Matsumoto T, Page CP, Wong RH, Jordan S, Smith F, Banik N, Halushka PV, Cavalla D, Rotshteyn Y, Kyle DJ, Burch RM, Chasin M. Gale DD, et al. Among authors: rotshteyn y. Pulm Pharmacol Ther. 2003;16(2):97-104. doi: 10.1016/S1094-5539(02)00175-X. Pulm Pharmacol Ther. 2003. PMID: 12670778 Review.
19 results